Preferred Label : Anti-BCMA/CD38/CD3 Trispecific Antibody ISB 2001;
NCIt synonyms : Anti-BCMA/Anti-CD38/Anti-CD3 Trispecific Antibody ISB 2001; TCE Trispecific Antibody ISB 2001; BCMA and CD38 Targeted TCE ISB 2001; BCMA x CD38 x CD3 TREAT Trispecific Antibody ISB 2001; Trispecific BCMA and CD38 T Cell Engager ISB 2001; BCMA x CD38 x CD3 Trispecific Antibody ISB 2001;
NCIt definition : A T-cell engager and trispecific antibody targeting the two tumor-associated antigens
(TAAs) CD38 and human B-cell maturation antigen (BCMA; tumor necrosis factor receptor
superfamily member 17; TNFRSF17), andd the T-cell surface antigen CD3, with potential
immunomodulating and antineoplastic activities. Upon intravenous administration, anti-BCMA/CD38/CD3
trispecific antibody ISB 2001 simultaneously targets and binds to CD38 and BCMA expressed
on tumor cells, and CD3 expressed on T-cells. The resulting cross-linkage activates
and redirects CTLs to CD38- and BCMA-expressing tumor cells. CD38, a type II transmembrane
glycoprotein, is present on various immune cells and hematologic malignancies; its
expression has been correlated with poor prognosis. BCMA, a member of the tumor necrosis
factor receptor superfamily that is specifically overexpressed on malignant plasma
cells, plays a key role in promoting plasma cell survival. Targeting both BCMA and
CD38 increases binding and specificity to tumor cells, such as myeloma cells, and
specifically increases death in tumors cells co-expressing CD38 and BCMA.;
Molecule name : ISB 2001; ISB-2001;
Origin ID : C200794;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
